At day 14, six of eight patients receiving the combination had HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan assay) and four of eight patients had HCV RNA levels below the limit of detection (10 IU/mL, according to the Roche TaqMan

Alfacell also released results from the first interim analysis following one-third of the required events (105 of 143 patients), showing an overall median survival of 12 months in the Onconase-plus doxorubicin-treated group vs. 10 months for patients receiving doxorubicin alone

The Phase III program will involve about 1,350 patients, with a primary endpoint of prevention of acute onset and delayed onset CINV in patients receiving either moderately or highly emetogenic chemotherapy

At 12 weeks, the Actilon combination therapy resulted in a 3.3 mean log reduction in HCV RNA level, compared to a 2.2 mean log reduction among patients receiving the control combination...After a two-week placebo run-in period, patients will be randomized to receive placebo or one of four doses of TH-070 (5 mg, 25 mg, 50 mg, 150 mg) daily for 28 days, and will be followed off of therapy for an additional three months.

At week 10 - after infusions at weeks zero, two, and six - 70 percent of patients treated with Remicade 3 mg/kg and 75 percent of patients receiving 5 mg/kg achieved at least a 75 percent improvement in psoriasis as measured by Psoriasis Area Severity Index

PSivida Ltd., of Perth, Australia, said three-year follow-up data from a trial of Retisert in diabetic macular edema concluded that significantly more patients receiving a Retisert implant had improved visual acuity of three or more lines compared to those receiving standard of care

VaxGen Inc., of Brisbane, Calif., said Phase II data of its attenuated smallpox vaccine, LC16m8, demonstrated that 100 percent of patients receiving the vaccine seroconverted and developed a lesion showing the vaccination is working, compared to 86 percent of patients receiving Dryvax, a nonattenuated vaccine